DOCSLIB.ORG

No. 135' Poisons EXPLANATORY NOTE

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
No. 135' Poisons EXPLANATORY NOTE No. 135' Poisons 435 EXPLANATORY NOTE (This note is not part of the Regulations, ,but is intended to indicate. their general purport.) These Regulations amend the Regulations regarding the provision of General Dental Services, as follows:- (1) by varying the. provisions concerning prior approval by the Dental Estimates Committ~e of estimates for dental treatment, where a variation or addition to an approved estimate becomes neces'sary d~ring treatme~t; " '" (2) by providing for the employment of, a,nd responsibility for, dental hygienists by dentists; (3) by withdrawing in respect of c~rtain items of treatment the requireme11t that the approval of the Dental 'Estimates Committee must be obtained before commencement of treatment; (4) by substituting a ,new list of prescribed drugs which a dentist may supply to or order for persons for whom he is providing general d~ntal services; , ' (5) by providing a fixed fee for gold fillings; (6) by making certain consequential and other minor alterations. 1960. No.135 [C] POISONS ORDER, DATED 31ST AUGUST, 1960; MADE BY THE MINISTER OF HOME AFFAIRS UNDER SUB-SECTION (6) OF SECTION TWENTY-SIX A OF THE MEDICINES, PHARMACY AND POISONS ACT (NORTHERN IRELAND), 1945. Whereas the Poisons Board, constituted in accordance with section twenty­ six of the Medicines, Pharmacy 'and Poisons Acf(Northern Ireland), 1945(a), has recommended to me that the list of the substances which are to be treated as poisons for the purposes of the Pharmacy and Poisons Acts (Northern Ireland), 1925 to 1955, and known as "the Poisons Schedule" for the purposes of those Acts, should be amended so that certain additional substances should be included in, and certain changes of nomenclature and arrangement made in Part I of the said schedule (which Part consists of those poisons which, subject to the provisions of the said Act, are not to be sold except by a person who is an authorised seller of poisons) and so that 'an additional substance should be included in Part II of the said schedule (which Part consists of those poisons which, subject to the provisions of the said Act, are not t9 be sold except by a person who is an authorised seller of poisons or who is authorised by the local authority) : Now, therefore, I, the Right Honourable Brian Faulkner, M.P., Minister of Home Affairs for Northern Ireland, in exercise of the powers conferred on me. by sub-section (6) of section twenty-six A of the Medicines, Pharmacy and POIsons Act (Northern Ireland), 1945, and of all other:pbwers enabling me in that behalf do hereby order as follows: - , ': " , , (a) 1945 c, 9, 436 Poisons NQ. 135 Citation and commencement 1. This Order may be cited as the Poison List (Amendment) Order (Northern Ireland), 1960,. a!ld shall come into operation on the 1st day of October, 1960. Amendments 2. The Poisons List Confirmation Order (Northern Ireland), 1956(a), (which constitutes "the Poisons Schedule" for the purposes of the Pharmacy and Poisons Acts (Northern Ireland), 1925 to 1955, shall be amended and varied as foHows, that is to say:- (a) Part I shall be amended and varied in the manner,spt;clfied in the First Schedule, (b) Part II shall be amended and varied in the manner speCified in the Second Schedule, and accordingly the list of substances in the Poisons Schedule which are to be treated as poisons for the purposes of the Phatmacy a,nd ;poisons Acts (Notthern Ireland), 1925 to 1955, shall be asset out in the Third Schedule. Dated this 31st day of August, 1960. Brian Faulkner, Minister of Home Affairs. FIRST SCHEDU:t:.,E Amendments and Variations in Part I of the Poisons Schedule In Part I of the Poisons Schedule- (a) there shall ,be inserted the foIlowi!lg items;- (i) "Acety1carbroma,I" "Azacvclonol; it!;) salts" "Benactyzine; its salts" ,. Benzethidine; its ,salts" ., 3-Benzylhydrazinocarbonyl-5-methylisooxazole; its salts" " BromvaletOlie " . .. Captodiame; its salts" " Carbromal" " 2-p-Chlorophenyl-3-methylbutane-2 : 3-diol " .. Chlorpropamide; its salts" , "Cyclophosphamide; its salts " "Dimenoxadole; its sal.ts" .. Furethidine; its salts" "4-Hydroxymethyl-2 : 2-diisop.J;'opyl-l : 3-dioxolan" "Hydroxyzine; its salts" " Imipramine;' its salts" " Mannomustine; its salts" "Mephenesin; its esters" " Meprobamate" , " Metformin; its salts" " Methocarbamol " "a-Methyl-phenethylhydrazine; its salts'" " Methyl phenidate; its salts " "Norcodeine' its salts" "Normorphi~e; its salts" (a) S.R. &; 9. (N:!.) '1956, No. 118. No. 135 Poisons 437 .. Phenazocine' its salts" ... Phenelzine; its salts " .. Phenformin; its salts·" .. Phenmetrazine; its salts" " Pipradrol; its salts " .. Thalidomide; its salts." ". Zoxazolamine; its salts" (ii) under the heading" Alkaloids "-. " Rauwolfia, alkaloids of" (iii) under the heading " Anti-histamine substances ,,~ " Buclizine " .. (p-Chlorophenylpyrid-2-ylmethyl) 2-dime~hyhiminoethyl ether" " 1-(4-p-Chlorophenyl-3-phenyl-but-2-enyl)-pyrrolidine " "'Chlorpheniramine " , . '.' Clemizole " " CycIizine " .. I-Dimethylamino-3-phenyl-3-(2-pyridyl)-propane'" .. Diphenylpyraline " " Doxylamine" " Isothipendyl " .. Mebhydrolin " " Mec1ozine'" " Thenalidine " "1r'iprolidine "; (b) for the item "3-(1O-Phenothiazinyl)propane substituted in the I-position; . its saIts; derivatives of 3-(10-Ph~nothiazinyl)propane substituted in the I-position; their salts" t4ere sh'a:ll be substituted the item "Phenothiazine, derivatives of; their salts; except promethazine, its salts and its molecular compounds"; (c) the items se.t out in sub-paragraph (i). of this paragraph shall be omitted and in substitution therefor' there shallbe inserted the items set out in sub-paragraph (ii)of this paragraph- . (i) "Beta-aminopropylbenzene; its salts; its N-alkyl derivatives; their salts; beta-aminoisdpropylbenzene; its salts; its N-alkyl derivatives; their salts" ' " Diacetyl-N-allylnormotphine; its salts" " Di-isopropyl fluorophosphonate'" " 1 : 4-Dimethanesulphonoxybutane; its salts " "Levorphan; its salts" "6-Mercaptopurine; its salt~"" ' " Metanitrophenol; orthonitrophenol; ,paranitrophenol " " Methadol; its salts" . " Methyldesomorphine; its salts '~ "Morpholinylethylmorphine; its salts" ." Oestrogenic substances,. natural and artificial .,' . "Para-aminobenzenesulphonamide; its salts; derivatives of para-ammo- benzenesulphonamide having any of the hydrogen atoms of the ,. '.' para-amino group or of' the sulphonamide group substituted by anpther radical; their salts '? " Para-amino-benzoic acid; esters of; their salts'" " 'Phenylacetylurea " " Tri-(2-chloroethyl)amine;' its salts'" " Triethanomelamine; its salts" "Tropine diphenylmethyl ether; its salts" (under the. heading" Anti-histamine substanceS") "Bromazine"; (ii) "B-Aminopropylbenzene;' its salts; its N-alkyl derivatives; their salts; . B-aminoisopropylbenzene; its salts; its N-alkyl derivatives; their salts" " Diacetylnalorphine;' its salts" " "' " Dyflos " ." -,;". '., 438 Poisons No. 135 " Busulphan; its salts" " Levorphanol; its salts" " Mercaptopurine; its salts" " m-Nitrophenol; o-nitrophenol; p-nitrophenol ,; "Dimepheptanol; its salts" . " Methyldesotphine; its salts" "Pho1codine; its salts" " . " Androgenic and oestrogenic· substances,' the' following; '-'-,- Benzoestrol '. Derivatives of stUbeIle, djbenzyl or naphthalene with oestrogenic activity; their esters . Steroid c~mpounds with andI;ogen~c or .oestrogenic activity; their esters. .. " p-Aminobenzenesulphonamide;' its salts; de~iv.a·ti~es· of p-amino­ benzenesulphonamide having any of the hydrogen atoms of the p-amino group or of the sulphonamidegroup"'substitutedby another· radical; their salts" " p-Amino-benzoic acid, esters of; their salts" " Phenacemide " " Trimustine; . its salts" "Tretamine; its salts" " Benztropine; its salts "; (under the heading" Anti-histamine substances") .i·Bromodiphenhydra­ mine "; (d) the following items under the heading" Alkaloids" shaJI Qe omitted, fiamely •• Acetyldihydrocodeine '~, " Acetyldihydrocodeinorie; .its estets ", " Apomorphine '~, "Benzoylmorphine ", "Benzylmorphine", •. Diacetyi. morphine '\ "Dihydrocodeine ",." Dihydrocodein<;>ne; its esters ", "Dipydro­ desoxymorphine ".. "Dihydrohydroxycodeinone; its. ester!? '-',' "Dihydro­ morphine; its esters", "Dihydromorphinone; its estets"· and" Ethylmor­ phine", and in substitution therefor there shall be inserted in the Schedule elsewhere than under that heading the following items- " Acetyldihydrocodeiile; its salts " " Apomorphine; its salts" "Benzoylmorphine; its salts" " Benzylmorphine; its salts" "Diacetylmorphine; its salts" "Dihydrocodeine; its salts" "Dihydrocodeinone; its salts; its esters; their salts ?' .~ Desomorphine; its salts" " Oxycodone; its salts; its esters; their salts" "Thebacon; its salts; its esters; their salts ". "Dihydromorphine; its salts; its estets; their 'saIts " "Hydromorphone; its salts; ·its esters; their salts" "Ethylmorphin~; its salts ". (e) in the item "Antimony,. Chlorides of; Oxides of Antimony; Sulphides of Antimony; Antimonates; Antimonites; Organic Compounds of Antimony", there shall be added -the words" except Antimony Trichlori<:ie ". (1) in the item conimencing Mercury, Oxides of; there shall be omitted the words" Mercuric Chloride; Metcuric Iodides ". SECOND SCHEDULE Variation in ParOl of the Poiso~s Schedule In Part II of the Poisons Schedule after the item " AmmQnia " there shall be inserted the item" Antimony Trichloride", ' No. /35 Poi$ons 439 THIRD SCI:JEDULE The Poisons ~chedule PART I Acetanilide; ·alkyl acetanilide's Acetylcarbromal Acetyldihydrocodeine; its salts Alkali fluorides
Load more

Recommended publications
  • (12) Patent Application Publication (10) Pub. No.: US 2010/0221245 A1 Kunin (43) Pub
    US 2010O221245A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2010/0221245 A1 Kunin (43) Pub. Date: Sep. 2, 2010 (54) TOPICAL SKIN CARE COMPOSITION Publication Classification (51) Int. Cl. (76) Inventor: Audrey Kunin, Mission Hills, KS A 6LX 39/395 (2006.01) (US) A6II 3L/235 (2006.01) A638/16 (2006.01) Correspondence Address: (52) U.S. Cl. ......................... 424/133.1: 514/533: 514/12 HUSCH BLACKWELL SANDERS LLP (57) ABSTRACT 4801 Main Street, Suite 1000 - KANSAS CITY, MO 64112 (US) The present invention is directed to a topical skin care com position. The composition has the unique ability to treat acne without drying out the user's skin. In particular, the compo (21) Appl. No.: 12/395,251 sition includes a base, an antibacterial agent, at least one anti-inflammatory agent, and at least one antioxidant. The (22) Filed: Feb. 27, 2009 antibacterial agent may be benzoyl peroxide. US 2010/0221 245 A1 Sep. 2, 2010 TOPCAL SKIN CARE COMPOSITION stay of acne treatment since the 1950s. Skin irritation is the most common side effect of benzoyl peroxide and other anti BACKGROUND OF THE INVENTION biotic usage. Some treatments can be severe and can leave the 0001. The present invention generally relates to composi user's skin excessively dry. Excessive use of some acne prod tions and methods for producing topical skin care. Acne Vul ucts may cause redness, dryness of the face, and can actually garis, or acne, is a common skin disease that is prevalent in lead to more acne. Therefore, it would be beneficial to provide teenagers and young adults.
    [Show full text]
  • Wo 2010/075090 A2
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date 1 July 2010 (01.07.2010) WO 2010/075090 A2 (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every C07D 409/14 (2006.01) A61K 31/7028 (2006.01) kind of national protection available): AE, AG, AL, AM, C07D 409/12 (2006.01) A61P 11/06 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, (21) International Application Number: DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/US2009/068073 HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, (22) International Filing Date: KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, 15 December 2009 (15.12.2009) ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, (25) Filing Language: English SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, (26) Publication Language: English TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 61/122,478 15 December 2008 (15.12.2008) US kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, (71) Applicant (for all designated States except US): AUS- ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, PEX PHARMACEUTICALS, INC.
    [Show full text]
  • Title 16. Crimes and Offenses Chapter 13. Controlled Substances Article 1
    TITLE 16. CRIMES AND OFFENSES CHAPTER 13. CONTROLLED SUBSTANCES ARTICLE 1. GENERAL PROVISIONS § 16-13-1. Drug related objects (a) As used in this Code section, the term: (1) "Controlled substance" shall have the same meaning as defined in Article 2 of this chapter, relating to controlled substances. For the purposes of this Code section, the term "controlled substance" shall include marijuana as defined by paragraph (16) of Code Section 16-13-21. (2) "Dangerous drug" shall have the same meaning as defined in Article 3 of this chapter, relating to dangerous drugs. (3) "Drug related object" means any machine, instrument, tool, equipment, contrivance, or device which an average person would reasonably conclude is intended to be used for one or more of the following purposes: (A) To introduce into the human body any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (B) To enhance the effect on the human body of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (C) To conceal any quantity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; or (D) To test the strength, effectiveness, or purity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state. (4) "Knowingly" means having general knowledge that a machine, instrument, tool, item of equipment, contrivance, or device is a drug related object or having reasonable grounds to believe that any such object is or may, to an average person, appear to be a drug related object.
    [Show full text]
  • Rhinitis - Allergic (1 of 15)
    Rhinitis - Allergic (1 of 15) 1 Patient presents w/ signs & symptoms of rhinitis 2 • Consider other classifi cations of rhinitis DIAGNOSIS No - Please see Rhinitis Is allergic rhinitis - Nonallergic disease confi rmed? management chart Yes 3 ASSESS DURATION & SEVERITY OF ALLERGIC RHINITIS A Non-pharmacological therapy • Allergen avoidance • Patient education VAS <5 VAS ≥5 B Pharmacological therapy B Pharmacological therapy • Antihistamines (oral/nasal), &/or • Corticosteroids (nasal), w/ or without • Corticosteroids (nasal), or • Antihistamines (nasal), or • Cromone (nasal), or • LTRA • Leukotriene receptor antagonists (LTRA)MIMS TREATMENT © See next page Specifi cally for patients w/ asthma Not all products are available or approved for above use in all countries. Specifi c prescribing information may be found in the latest MIMS. B167 © MIMS Pediatrics 2020 Rhinitis - Allergic (2 of 15) Previously treated symptomatic Previously treated symptomatic patient (VAS <5) on antihistamines patient (VAS ≥5) on intensifi ed (oral/nasal) &/or corticosteroids (nasal) therapy w/ corticosteroids (nasal) w/ or without antihistamines (nasal) Intermittent Persistent symptoms, symptoms or without allergen w/ allergen exposure exposure B Pharmacological therapy B Pharmacological therapy • Step down or discontinue therapy • Continue or step up therapy Untreated REASSESS DISEASE SEVERITY VAS symptomatic patient DAILY UP TO DAY 3 (VAS <5 or ≥5) 4 CONTINUE Yes THERAPY & STEP EVALUATION VAS <5 DOWN THERAPY1 Improvement of symptoms? No VAS ≥5 B Pharmacological therapy • Step-up therapy REASSESS DISEASE SEVERITY MIMSVAS DAILY UP TO DAY 7 4 Yes EVALUATION VAS <5 Improvement of symptoms? No TREATMENT © VAS ≥5 See next page Continue therapy if symptomatic; consider step-down or discontinuation of therapy if symptoms subside Not all products are available or approved for above use in all countries.
    [Show full text]
  • Pharmaceutical Appendix to the Tariff Schedule 2
    Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM LIDADRONICUM 63132-38-7 ABAFUNGIN 129639-79-8 ACIDUM SALCAPROZICUM 183990-46-7 ABAMECTIN 65195-55-3 ACIDUM SALCLOBUZICUM 387825-03-8 ABANOQUIL 90402-40-7 ACIFRAN 72420-38-3 ABAPERIDONUM 183849-43-6 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABATACEPTUM 332348-12-6 ACITEMATE 101197-99-3 ABCIXIMAB 143653-53-6 ACITRETIN 55079-83-9 ABECARNIL 111841-85-1 ACIVICIN 42228-92-2 ABETIMUSUM 167362-48-3 ACLANTATE 39633-62-0 ABIRATERONE 154229-19-3 ACLARUBICIN 57576-44-0 ABITESARTAN 137882-98-5 ACLATONIUM NAPADISILATE 55077-30-0 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURINUM 178535-93-8 ACOLBIFENUM 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDUM 185106-16-5 ACAMPROSATE 77337-76-9
    [Show full text]
  • Proposed Changes to the 2021 FEI Equine Prohibited Substances List (EPSL) (Effective from 01.01.2022)
    Proposed changes to the 2021 FEI Equine Prohibited Substances List (EPSL) (effective from 01.01.2022) SUBSTANCE NAME CURRENT PROPOSED COMMENT STATUS EPSL CATEGORY ACETYLCHOLINESTERASE INHIBITOR Used in the treatment of Edrophonium Controlled Banned myasthenia gravis and Medication Substance has no legitimate use in the treatment of sports horses Used to increase Huperzine A Unlisted Banned alertness and treat Substance myasthenia gravis. The substance has no legitimate use in the treatment of sports horses. AMIDES Palmitoylethanolamid Banned Controlled Used in the treatment of Substance Medication joint pain ANGIOTENSIN CONVERTING ENZYME INHIBITORS Enalapril Controlled Banned The substance carries a Medication Substance high risk of abuse and has no legitimate use in the sports horse Enalaprilat Controlled Banned The substance carries a Medication Substance high risk of abuse and has no legitimate use in the sports horse Lisinopril Controlled Banned The substance carries a Medication Substance high risk of abuse and has no legitimate use in the sports horse Moexipril Controlled Banned The substance carries a Medication Substance high risk of abuse and has no legitimate use in the sports horse 1 Perindoprilat Controlled Banned The substance carries a Medication Substance high risk of abuse and has no legitimate use in the sports horse ANTIHISTAMINES Antazoline Controlled Banned The substance has no Medication Substance legitimate use in the sports horse Azatadine Controlled Banned The substance has Medication Substance sedative effects
    [Show full text]
  • Vr Meds Ex01 3B 0825S Coding Manual Supplement Page 1
    vr_meds_ex01_3b_0825s Coding Manual Supplement MEDNAME OTHER_CODE ATC_CODE SYSTEM THER_GP PHRM_GP CHEM_GP SODIUM FLUORIDE A12CD01 A01AA01 A A01 A01A A01AA SODIUM MONOFLUOROPHOSPHATE A12CD02 A01AA02 A A01 A01A A01AA HYDROGEN PEROXIDE D08AX01 A01AB02 A A01 A01A A01AB HYDROGEN PEROXIDE S02AA06 A01AB02 A A01 A01A A01AB CHLORHEXIDINE B05CA02 A01AB03 A A01 A01A A01AB CHLORHEXIDINE D08AC02 A01AB03 A A01 A01A A01AB CHLORHEXIDINE D09AA12 A01AB03 A A01 A01A A01AB CHLORHEXIDINE R02AA05 A01AB03 A A01 A01A A01AB CHLORHEXIDINE S01AX09 A01AB03 A A01 A01A A01AB CHLORHEXIDINE S02AA09 A01AB03 A A01 A01A A01AB CHLORHEXIDINE S03AA04 A01AB03 A A01 A01A A01AB AMPHOTERICIN B A07AA07 A01AB04 A A01 A01A A01AB AMPHOTERICIN B G01AA03 A01AB04 A A01 A01A A01AB AMPHOTERICIN B J02AA01 A01AB04 A A01 A01A A01AB POLYNOXYLIN D01AE05 A01AB05 A A01 A01A A01AB OXYQUINOLINE D08AH03 A01AB07 A A01 A01A A01AB OXYQUINOLINE G01AC30 A01AB07 A A01 A01A A01AB OXYQUINOLINE R02AA14 A01AB07 A A01 A01A A01AB NEOMYCIN A07AA01 A01AB08 A A01 A01A A01AB NEOMYCIN B05CA09 A01AB08 A A01 A01A A01AB NEOMYCIN D06AX04 A01AB08 A A01 A01A A01AB NEOMYCIN J01GB05 A01AB08 A A01 A01A A01AB NEOMYCIN R02AB01 A01AB08 A A01 A01A A01AB NEOMYCIN S01AA03 A01AB08 A A01 A01A A01AB NEOMYCIN S02AA07 A01AB08 A A01 A01A A01AB NEOMYCIN S03AA01 A01AB08 A A01 A01A A01AB MICONAZOLE A07AC01 A01AB09 A A01 A01A A01AB MICONAZOLE D01AC02 A01AB09 A A01 A01A A01AB MICONAZOLE G01AF04 A01AB09 A A01 A01A A01AB MICONAZOLE J02AB01 A01AB09 A A01 A01A A01AB MICONAZOLE S02AA13 A01AB09 A A01 A01A A01AB NATAMYCIN A07AA03 A01AB10 A A01
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2002/0102215 A1 100 Ol
    US 2002O102215A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2002/0102215 A1 Klaveness et al. (43) Pub. Date: Aug. 1, 2002 (54) DIAGNOSTIC/THERAPEUTICAGENTS (60) Provisional application No. 60/049.264, filed on Jun. 6, 1997. Provisional application No. 60/049,265, filed (75) Inventors: Jo Klaveness, Oslo (NO); Pal on Jun. 6, 1997. Provisional application No. 60/049, Rongved, Oslo (NO); Anders Hogset, 268, filed on Jun. 7, 1997. Oslo (NO); Helge Tolleshaug, Oslo (NO); Anne Naevestad, Oslo (NO); (30) Foreign Application Priority Data Halldis Hellebust, Oslo (NO); Lars Hoff, Oslo (NO); Alan Cuthbertson, Oct. 28, 1996 (GB)......................................... 9622.366.4 Oslo (NO); Dagfinn Lovhaug, Oslo Oct. 28, 1996 (GB). ... 96223672 (NO); Magne Solbakken, Oslo (NO) Oct. 28, 1996 (GB). 9622368.0 Jan. 15, 1997 (GB). ... 97OO699.3 Correspondence Address: Apr. 24, 1997 (GB). ... 9708265.5 BACON & THOMAS, PLLC Jun. 6, 1997 (GB). ... 9711842.6 4th Floor Jun. 6, 1997 (GB)......................................... 97.11846.7 625 Slaters Lane Alexandria, VA 22314-1176 (US) Publication Classification (73) Assignee: NYCOMED IMAGING AS (51) Int. Cl." .......................... A61K 49/00; A61K 48/00 (52) U.S. Cl. ............................................. 424/9.52; 514/44 (21) Appl. No.: 09/765,614 (22) Filed: Jan. 22, 2001 (57) ABSTRACT Related U.S. Application Data Targetable diagnostic and/or therapeutically active agents, (63) Continuation of application No. 08/960,054, filed on e.g. ultrasound contrast agents, having reporters comprising Oct. 29, 1997, now patented, which is a continuation gas-filled microbubbles stabilized by monolayers of film in-part of application No. 08/958,993, filed on Oct.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8.242,110 B2 Deregnaucourt Et Al
    USOO824211 OB2 (12) United States Patent (10) Patent No.: US 8.242,110 B2 Deregnaucourt et al. (45) Date of Patent: Aug. 14, 2012 (54) USE OF ANTIHISTAMINEAGENTS FOR THE FOREIGN PATENT DOCUMENTS PREVENTIVE OR EARLY TREATMENT OF FR 2802 101 A1 6, 2001 INFLAMMATORY SYNDROMES, IN JP 4-89428 A 3, 1992 PARTICULAR THOSE TRIGGERED BY JP 2001-151677 A 6, 2001 TOGAVIRUSES WO WO-96,04787 A1 2, 1996 (75) Inventors: Jean Deregnaucourt, Paris (FR): OTHER PUBLICATIONS Etienne Andre, Seyssinet-Pariset (FR): Wilson, Annals of Rheumatic Diseases, 1953; 12(1):38-39.* Jacky Tisne-Versailles, Castres (FR) Storms, Journal of Allergy and Clinical Immunology, 2004; 114:S146-153.* (73) Assignee: Pierre Fabre Medicament, Satake et al., Journal of Cardiovascular Pharmacology, Boulogne-Billancourt (FR) 1994:23(4):669-673 (abstract only).* Toovey et al., Travel Medicine and Infectious Disease, vol.2, No. 3-4, (*) Notice: Subject to any disclaimer, the term of this 2004, pp. 189-191. patent is extended or adjusted under 35 Suhrbier et al., Current Opinion in Rheumatology, vol. 16, No. 4. U.S.C. 154(b) by 809 days. 2004, pp. 374-379. Stocks et al., Australian Family Physician, vol. 26, No. 6, Jun. 1997. (21) Appl. No.: 12/224,830 pp. 710-717. Paganin et al., Presse Medicale 2006, vol. 35. No. 4 II, 2006, pp. (22) PCT Filed: Mar. 9, 2007 641-646. Ware et al., Medical Care, vol. 34, No. 3, 1996, pp. 220-233. (86). PCT No.: PCT/EP2007/052237 Bruce et al., The Journal of Rheumatology, vol. 30, No. 1, 2003, pp.
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • Thesis Rests with Its Author
    University of Bath PHD Resolution of enantiomers using cyclodextrins in NMR and HPLC Cooper, Andrew Donovan Award date: 1991 Awarding institution: University of Bath Link to publication Alternative formats If you require this document in an alternative format, please contact: [email protected] General rights Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights. • Users may download and print one copy of any publication from the public portal for the purpose of private study or research. • You may not further distribute the material or use it for any profit-making activity or commercial gain • You may freely distribute the URL identifying the publication in the public portal ? Take down policy If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim. Download date: 06. Oct. 2021 Resolution of Enantiomers using Cyclodextrins in NMR and HPLC Submitted by Andrew Donovan Cooper, B.Sc., GRSC, for the degree of Ph.D. of the University of Bath 1991 COPYRIGHT Attention is drawn to the fact that copyright of this thesis rests with its author. This copy of the thesis has been supplied on condition that anyone who consults it is understood to recognise that its copyright rests with its author and that no quotation from the thesis and no information from it may be published without the prior written consent of the author.
    [Show full text]
  • 2 12/ 35 74Al
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date 22 March 2012 (22.03.2012) 2 12/ 35 74 Al (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 9/16 (2006.01) A61K 9/51 (2006.01) kind of national protection available): AE, AG, AL, AM, A61K 9/14 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, (21) International Application Number: DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/EP201 1/065959 HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, (22) International Filing Date: KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, 14 September 201 1 (14.09.201 1) ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, (25) Filing Language: English RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, (26) Publication Language: English TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: 61/382,653 14 September 2010 (14.09.2010) US (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (71) Applicant (for all designated States except US): GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, NANOLOGICA AB [SE/SE]; P.O Box 8182, S-104 20 ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, Stockholm (SE).
    [Show full text]